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Abstract
Background: Cystic fibrosis (CF) is a genetically inherited, life-limiting condition, affecting ~90,000 people globally.
Physical activity (PA) and exercise form an integral component of CF management, and have been highlighted by
the CF community as an area of interest for future research. Previous reviews have solely focused on PA or
structured exercise regimens independent of one another, and thus a comprehensive assessment of the physical
health benefits of all PA, including exercise, interventions, is subsequently warranted. Therefore, the purpose of this
review is to evaluate the effects of both PA and exercise upon outcomes of physical health and healthcare
utilisation in people with CF.
Methods: A systematic review has been registered and reported in line with Preferred Reporting Items for
Systematic Reviews and Meta-Analysis-P guidelines. This will include randomised control trials on the effects of PA
and exercise, relative to usual treatment, upon people with CF. Primary outcomes will include variables associated
with fitness, PA, lung health, inflammation, body composition, glycaemic control and patient-reported outcomes.
Secondary outcomes will include adverse events and healthcare utilisation. Searches will be undertaken in Ovid
MEDLINE, OVID EMBASE, PsychINFO, ERIC, SPORTDiscus, ASSIA, CCTR, CINHAL and Web of Science databases, and
will be searched from date of inception onwards. Two reviewers will independently screen citations and abstracts,
and full-texts, for inclusion and data extraction, respectively. Methodological quality will be assessed using the
Cochrane Risk of Bias-2 tool. If feasible, random-effects meta-analyses will be conducted where appropriate.
Additional analyses will explore potential sources of heterogeneity, such as age, sex, and disease severity.
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: C.A.Williams@exeter.ac.uk
1Children’s Health and Exercise Research Centre, Sport and Health Sciences,
University of Exeter, Heavitree Road, Exeter EX1 2LU, UK
2Royal Devon and Exeter NHS Foundation Trust Hospital, Barrack Road,
Exeter EX2 5DW, UK
Full list of author information is available at the end of the article
Tomlinson et al. Systematic Reviews           (2021) 10:64 
https://doi.org/10.1186/s13643-021-01614-8
(Continued from previous page)
Discussion: This systematic review will build on previous research, by comprehensively assessing the impact of
both PA and exercise upon physical health and healthcare utilisation in people with CF. Results of this review will
be utilised to inform discussions that will ultimately result in a consensus document on the impact of physical
activity and exercise for people with CF.
Systematic review registration: PROSPERO CRD42020184411
Keywords: Pulmonary disease, Movement, Lifestyle, Healthcare
Introduction
Cystic fibrosis (CF) is a genetically inherited condition
which affects multiple organ systems. Disease progres-
sion is predominantly observed through deteriorating
lung function [1]. Currently, there are ~90,000 people
globally with CF [2], the majority of whom are in Europe
[3] and North America [4, 5]. Substantial growth in the
size of the CF population is anticipated [6], accompanied
by an increase in life expectancy into the fifth decade of
life [7]. Presently, there is no cure for CF, and therefore
it is a life-long condition that is ‘managed’ as opposed to
‘cured’. Whilst a number of promising pharmacological
advances have been made [8], CF is still fundamentally
managed using a combination of medication, nutrition,
physiotherapy and physical activity (PA), or more specif-
ically, exercise [9].
The outcomes of a recent patient-driven research pri-
ority partnership [10], highlighted the need for research
to advance our understanding of the benefits of PA and
exercise [11], and simplify treatment burden in CF [10].
Previously, the time spent being physically active [12,
13], as well as the associations between PA and health
[13] and the effect of PA [14] and structured exercise
interventions [15] for CF, has been systematically
reviewed. These reviews have concluded that individuals
with CF spent a similar amount of time being physically
active relative to non-CF peers [12, 13], and that despite
heterogeneity in study designs, interventions and out-
comes, there was no evidence to actively discourage PA
or exercise in CF [15].
However, despite being reviewed independently previ-
ously, PA and exercise are not mutually exclusive con-
structs. Exercise is a structured subcomponent of PA
conducted for the inherent health associations. Nonethe-
less, evidence suggests that all PA, irrespective of pur-
pose or intensity, is associated with improved health
status in CF [12–15]. Therefore, both PA and exercise
must be considered when attempting to integrate activity
into the daily lives of those with CF, and not solely the
prescription of structured exercise per se. Consequently,
an updated review that simultaneously, and universally,
accounts for all aspects of PA, including exercise, is
warranted.
The main objective of this systematic review is to iden-
tify the effect of both PA and exercise upon parameters
of physical health and healthcare utilisation, relative to
usual care, in people with CF. In addition, a secondary
objective is to identify if different effects are present in
people of differing age, sex, and disease status, and
whether certain components of interventions are linked
to favourable outcomes in people with CF (e.g. delivery
method, modality, intensity, frequency, length).
Methods
This review has been designed by experts in PA, exercise
science and the physiotherapy management of CF. The
present protocol has been registered on the PROSPERO
database (CRD42020184411) and is being reported in ac-
cordance with the reporting guidance provided in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis–Protocol (PRISMA-P) statement [16, 17]
(see checklist in Additional file 1). If any updates to the
protocol are required during the process of undertaking
the review, these will be appropriately updated on the
PROSPERO database, and detailed in the subsequent
systematic review to be published.
Eligibility criteria
Studies will be limited to those published in English. No
restrictions will be placed on publication dates. Studies
will be included in this systematic review based upon a
series of pre-planned inclusion and exclusion criteria for
the following domains:
Participants
This review will solely include individuals with a clinical
diagnosis of CF [18]. If studies include people with CF
as part of a wider population (e.g. people with a pulmon-
ary disease), results will be included in the systematic re-
view provided information for the CF participants can
be successfully retrieved in isolation from other non-CF
groups. If CF-specific data cannot successfully be re-
trieved from published manuscripts, study authors will
be contacted for data. There is no restriction on age.
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Interventions
Studies must include any intervention based on promot-
ing PA, sport, exercise, recreation, or movement. Given
that multiple factors can be considered when describing
interventions [19], and the generally complex and broad
nature of PA and exercise interventions, there exists a
possibility of inadvertently excluding studies if explicit
interventions are defined in advance. Therefore, no cri-
teria related to time frame, location, setting or delivery
provider will be used to limit inclusion and thus
maximise potential inclusion of eligible studies. Inter-
ventions where PA and/or exercise form a secondary
sub-component of a wider intervention (e.g. nutritional,
educational, pharmacological) will be excluded from this
review if the effects of PA/exercise alone cannot be suc-
cessfully isolated and retrieved. If exercise-specific data
cannot successfully be retrieved from published manu-
scripts, study authors will be contacted for data.
Comparison
Primarily, interventions will be compared against pa-
tients receiving their usual clinical care (i.e. no interven-
tion). Secondly, studies that compare two intervention
arms within a single cohort of people with CF (e.g. high
intensity vs. low intensity exercise) will also be included
in an effort to identify dose-response effects.
Outcomes
Factors associated with physical health and healthcare
utilisation will be included in the review, but will not be
explicitly searched for upon the basis of the following
outcomes. As stated, previous reviews [13, 15] have
identified heterogeneity in the variables that have been
reported and therefore outcomes will be obtained at the
extraction stage, provided that the intervention has met
the stated criteria above. It is anticipated that the pri-
mary outcomes will be related to (1) fitness: including,
but not limited to, muscle strength, aerobic fitness and
walking distance; and (2) physical activity (objective and
subjective outcomes): including, but not limited to, total
energy expenditure, step count and time spent in light,
moderate and vigorous physical activity; (3) lung health:
including, but not limited to, forced expiratory volume
in 1 s (FEV1), forced vital capacity (FVC), tiffeneau index
(FEV1/FVC), peak expiratory flow (PEF) and lung clear-
ance index (LCI); (4) inflammation: including, but not
limited to, C-reactive protein (CRP) and cytokines such
as interleukin 6 (IL-6) and 8 (IL-8); (5) body compos-
ition: including, but not limited to, fat mass, fat-free
mass, body mass index (BMI) and bone mineral density;
(6) glycaemic control: including, but not limited to,
blood glucose levels such as glycated haemoglobin
(HbA1c); (7) patient-reported outcome measures: in-
cluding, but not limited to, quality of life and its
components, breathlessness and fatigue. It is anticipated
secondary outcomes will be related to (1) serious adverse
events: which may take multiple forms such as sprains,
strains, fractures, haemoptysis, exacerbations and desat-
uration; (2) healthcare utilisation: which may take mul-
tiple forms, such as inpatient hospital days, medication
usage and healthcare costs.
Study design
This systematic review will be limited to randomised
control trials (RCT) comparing PA and/or exercise inter-
ventions (as above) to standard CF care (i.e. no interven-
tion), and/or another PA/exercise intervention.
Information sources and search
The following electronic databases will be searched:
Ovid MEDLINE, OVID EMBASE, PsychINFO, ERIC,
SPORTDiscus, ASSIA, CCTR, CINHAL, and Web of
Science. These databases will be searched from respect-
ive dates of inception onwards. Grey literature will not
be included to ensure quality standards are met. The lit-
erature searches will be initially designed by the research
team, and conducted by an information specialist, who
will also customise the search for each database. The
search will include a broad range of terms and keywords
related to PA, exercise and RCTs. The search terms have
been restricted to ‘Population/Intervention/Comparison/
Outcome’ (PICO) domains of participants, intervention,
and study design. Given the wide heterogeneity in out-
come variables available, and the way they are reported
as has been previously explained, these have been omit-
ted from the search strategy in order to increase returns.
A draft search strategy, utilising these domains, is pro-
vided in Table 1.
Records will be imported and managed via online
evidence synthesis software (Covidence systematic
review software, Veritas Health Innovation, Melbourne,
Australia).
Data selection and collection process
All articles returned from searches will be screened by
two independent researchers. First, titles and abstracts of
identified papers will be assessed in relation to afore-
mentioned eligibility criteria. Second, eligible articles will
have full-texts retrieved and then screened in full, again
against the aforementioned eligibility criteria. If neces-
sary, any disagreements that arise will be resolved via
discussion with a third reviewer. A flow chart, detailing
inclusion, and exclusion of studies at each stage, will be
included in the final, published review.
Data extraction
Data will be extracted independently by two reviewers
using a standardised data extraction template designed
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for this purpose (Additional file 2). Data will be
extracted on the following: intervention design and de-
livery (including, but not limited to location, modality,
intensity, frequency, length of intervention), participant
characteristics (sex, age and disease severity of both con-
trol and intervention group(s)), and outcomes (variables,
and magnitude of change from baseline for continuous
data). Disagreements will be resolved via discussion with
a third reviewer if necessary. This data extraction will be
piloted on five randomly selected papers by two inde-
pendent authors. If extracted results are in agreement,
this extraction template will be uniformly utilised by all
authors.
The majority of outcomes produce objective measures,
and these will be prioritised over subjective measures
where possible. Data will be extracted based upon both
(where possible): (1) absolute differences in outcomes at
follow up; and (2) differences between groups (i.e. inter-
vention vs. control) at follow-up. This will allow for as-
sessment of data if studies report outcomes in differing
formats.
Risk of bias assessment
Risk of bias (RoB) of individual studies will be assessed
using the RoB2 Tool for RCTs [20]. Assessments will be
made by two reviewers independently, with any disagree-
ments being resolved via discussion with a third reviewer
when necessary. Studies identified as being at high risk
of bias will be included, although the quality of each
study will be presented in results and will also be narra-
tively discussed.
Synthesis
Data synthesis will occur in several stages. Initially, sum-
mary tables will be created to detail characteristics of
each study included in the final review. This will include
the aforementioned data to be extracted using Add-
itional file 2 (intervention design and delivery, partici-
pant characteristics and outcomes). Absolute differences
in outcomes at follow-up, and mean differences between
groups (i.e. intervention vs. control) will be reported in
tables, as well as standardised mean differences for out-
comes that are reported in more than one way (e.g.
FEV1 as L, or %predicted). Additional narrative discussion
will also be provided.
Secondly, meta-analyses will be undertaken for pri-
mary outcomes where possible, using data pooled
from each study. Since heterogeneity is expected a
priori, we will estimate the pooled effect and its 95%
confidence interval using the random effects model,
which assumes the study effects follow a normal dis-
tribution, considering both within- and between-study
variation. Pooled effect sizes, using Hedges g, will be
interpreted with reference to Cohen’s thresholds [21]:
trivial (<0.2), small (0.2 to <0.5), moderate (0.5 to <
0.8) and large (≥0.8); whereby positive effect size
values indicate higher scores of the outcome in favour
of the PA/exercise group. All secondary outcomes,
and non-continuous primary outcomes (e.g. categor-
ical data), will be reported using Synthesis Without
Meta-analysis (SWiM) guidelines [22].
If studies have two CF groups (e.g. different exercise
intensities or protocols), multilevel models will be used
as their data will be analysed independently with the
control group, thus yielding multiple effect sizes for
those studies and outcomes. Both research study and
intra-study groups will be included as random effects in
the model. Cluster robust estimates will be produced,
weighted by inverse sampling variance to account for
the within- and between-study variance (tau-squared).
Restricted maximal likelihood estimation will be used in
all models.
Finally, meta-regression will be utilised to determine
differences between sub-groups based upon disease se-
verity (FEV1% categories: ≥70, 40-69, <40), age (<18
years, ≥18 years) and sex (male, female), all of which are
significant predictors for long-term outcomes and sur-
vival in CF [7, 23]. Moreover, the impact of differing de-
livery methods, modalities, intensities, frequencies, and
lengths of interventions will also be investigated via
meta-regression. Analyses will be contingent on a suffi-
cient number of studies (≥10) being found [24]. These
analyses will use age, sex and disease severity as modera-
tors of PA or exercise. If appropriate (i.e. a sufficient ra-
tio of studies to co-variates are found), multilevel
models will be produced for each sub-group (e.g. sex,
Table 1 Draft search strategy
Domain Terms
Population cystic fibrosis OR CF
Intervention physical activ* OR exercis* OR sport* OR recreation* OR move* OR yoga OR Tai Chi OR walk* OR run OR runn* OR play* OR jog* OR
cycl* OR game* OR inactive* OR sedentary OR swim* OR hike OR hiking* OR fitness OR gym* OR resistance OR aerobic OR leisure time
OR active travel OR jumping OR danc*
Study
design
random* OR control trial OR RCT OR clinical trial OR randomly OR groups OR allocat* OR crossover OR (((systematic OR state-of-the-art
OR scoping OR literature OR umbrella) ADJ (review* OR overview* OR assessment*)) OR “review* of reviews” OR meta-analy* OR metaa-
naly* OR ((systematic OR evidence) ADJ1 assess*) OR “research evidence” OR metasynthe* OR meta-synthe*).tw. OR exp Review Litera-
ture as Topic/ OR exp Review/ OR Meta-Analysis as Topic/ OR Meta-Analysis/ OR “systematic review”/
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age, FEV1 category) and a fixed-effects with moderators
model used to compare the models to ascertain whether
there was a significant difference (p<0.05). Sensitivity
analyses will be performed using the leave-one-out
method to examine the impact of removal of individual
effect sizes. Heterogeneity will again be examined
through the I2 statistic, with I2>50% indicating ‘substan-
tial’ heterogeneity [24]. If meta-regression is not possible
due to insufficient power, the sub-group analyses will be
undertaken, based upon aforementioned categories of
disease severity, age and sex. If quantitative syntheses
are not possible for determining differences between
sub-groups and intervention methods, the aforemen-
tioned SWiM guidelines [22] will be utilised to report
findings.
All meta-analyses will be undertaken using RevMan
(Review Manager v5.4; The Nordic Cochrane Centre,
The Cochrane Collaboration, Copenhagen, Denmark)
and Stata (Stata v16; StataCorp LLC, College Station TX,
USA) software programmes.
Meta-bias
To determine whether publication bias is present, it will
be examined using Egger’s linear regression test for fun-
nel plot asymmetry [25], and graphically presented by
contour-enhanced funnel plots with Duval and Twee-
die’s trim and fill used.
Grading of evidence
Certainty of evidence for outcomes will be judged using
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) methodology [26, 27]. This will
be undertaken by two independent reviewers, who will
examine the study limitations, publication bias, impreci-
sion, inconsistency and indirectness. The evidence will
then be classified as high, moderate, low or very low.
Discussion
It is well established that PA and exercise, are integral
components in the management of CF [9], and consult-
ation with the CF community has identified exercise as a
research priority [10]. However, the specific effects of
PA and/or exercise interventions on physical markers of
health in CF have not been fully quantified to date. In-
deed, previous reviews have solely focused on structured
exercise [15]. Whilst such reviews are useful, it is im-
portant to ensure that all interventions that target im-
provements in habitual PA, exercise programmes that
do not have set structures, or generalised increases in
movement away from a prescriptive framework, are in-
corporated. Therefore, the results of this systematic re-
view will pool findings of high-quality studies, by only
extracting RCTs, to determine true effects of PA and ex-
ercise interventions in this patient population. Whilst
RCTs tend to result in higher quality evidence, by only
including RCTs within the protocol and therefore omit-
ting observational and non-randomised control studies,
it is feasible that the effect of PA, or exercise, on some
markers of physical health and healthcare utilisation
may not be established. Moreover, the broad range of
ways in which PA and exercise interventions can be im-
plemented, such as differing modalities, locations, fre-
quency, intensity, materials and procedures [19] may
result in an under-powering of meta-analyses due to an
inability to pool data from independent studies. Whilst
this may initially be perceived as a limitation, this could
simultaneously provide the impetus for researchers and
clinicians to standardise future interventions to deter-
mine true effects of each component of delivery.
Whilst this systematic review is focused on outcomes
related to physical health and healthcare utilisation, the
importance of PA, or exercise, for mental health in CF
should not be ignored or understated. Therefore, a sep-
arate systematic review has been developed to establish
the effects of PA and exercise upon parameters of men-
tal health in CF (PROSPERO: CRD42019151034). The
results of these systematic reviews, focusing on physical
and mental health outcomes, will then be utilised to in-
form discussions amongst an international panel of
experts in exercise and CF, to create a consensus docu-
ment on the impact of PA and exercise for people with
CF. Both the findings of the present systematic review,
and the anticipated consensus document, will be dissem-
inated via conference presentations and peer-reviewed
academic journals.
In summary, by establishing the effect, and the associ-
ated magnitude, of any PA, or exercise intervention,
findings can influence guidelines and consensus docu-
ments that are utilised by clinical teams in daily practice.
Thus, ultimately, such a systematic process can, in turn,
enhance the care of people with CF.
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